This was characterized by the suppression of disease activity, as well as systemic pro-inflammatory mediators such as IL-6 in the serum, and potent inflammatory mediators such as TNF-α in tissues such as muscle, underpinning elements of it therapeutic efficacy in other disease settings such as Duchenne muscular dystrophy [26]. The gene discussed is IL6; the disease is Duchenne muscular dystrophy.